Publications by authors named "Mark Yan"
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)-an open-label, global, multicohort trial-evaluated the safety and efficacy of first-line targeted therapies or immunotherapy in patients with unresectable Stage IIIB or IV advanced or metastatic non-small cell lung cancer who were selected for biomarker status using blood-based targeted next-generation sequencing. In the Phase 3 cohort C evaluating blood-based (b)TMB as a biomarker of atezolizumab efficacy, patients with bTMB of ≥10 (N = 471) were randomized 1:1 to receive atezolizumab or platinum-based chemotherapy per local standard of care.
View Article and Find Full Text PDFArticle Synopsis
- This study assessed atezolizumab with guadecitabine in patients with relapsed/refractory (R/R) and first-line acute myeloid leukemia (AML), focusing on safety and effectiveness.
- Sixteen patients participated, with a median age of 73, and all experienced adverse events (AEs), with 93.8% reporting severe AEs.
- Due to high mortality (87.5% during study) and limited therapeutic response, including only one partial response, the study was stopped early, indicating poor overall effectiveness and safety for this treatment combination.
We present primary results from the phase 1b GO29754 study evaluating the safety and tolerability of atezolizumab, a programmed death-ligand 1 inhibitor, alone and in combination with azacitidine, a hypomethylating agent (HMA), in patients with relapsed/refractory (R/R) or HMA-naïve myelodysplastic syndrome (MDS). Patients with R/R MDS received atezolizumab for 12 months (cohort A) or atezolizumab plus azacitidine for 6 cycles followed by atezolizumab as maintenance for 8 cycles (cohort B). Patients with HMA-naïve MDS received atezolizumab plus azacitidine until loss of clinical benefit (cohort C).
View Article and Find Full Text PDFArticle Synopsis
- Diffuse large B-cell lymphoma (DLBCL) is commonly treated with a regimen called R-CHOP, but only about 60% of patients are cured.
- A clinical trial tested a modified treatment called pola-R-CHP, substituting vincristine with polatuzumab vedotin.
- Results showed that patients treated with pola-R-CHP had significantly better progression-free survival rates compared to those on standard R-CHOP, although overall survival rates were similar in both groups.
Introduction: The Blood First Assay Screening Trial is an ongoing open-label, multicohort study, prospectively evaluating the relationship between blood-based next-generation sequencing (NGS) detection of actionable genetic alterations and activity of targeted therapies or immunotherapy in treatment-naive advanced or metastatic NSCLC. We present data from the ALK-positive cohort.
Methods: Patients aged more than or equal to 18 years with stage IIIB or IV NSCLC and ALK rearrangements detected by blood-based NGS using hybrid capture technology (FoundationACT) received alectinib 600 mg twice daily.
Background: Polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, has demonstrated activity as a single agent and in combination with rituximab in relapsed or refractory diffuse large B-cell lymphoma. In this study, we evaluated the safety and preliminary activity of polatuzumab vedotin in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, and prednisone (CHP) in patients with previously untreated diffuse large B-cell lymphoma.
Methods: This was an open-label, non-randomised study composed of a phase 1b dose escalation and a phase 2 dose expansion at 11 hospitals and health centres in the USA and France.